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Background
Omalizumab is a humanized anti-immunoglobulin E (IgE)
monoclonal antibody that has been approved as add-on
therapy for the treatment of adults with moderate-to-
severe (United States) or severe (Europe) allergic asthma,
inadequately controlled after treatment with high-dose
inhaled corticosteroids plus long-acting b-agonists. The
clinical efficacy of Omalizumab has not only been shown
in the treatment of severe uncontrolled asthma, but also in
the treatment of nasal polyposis and comorbid asthma.
The aim of this analysis was to examine whether the diag-
nosis of chronic rhinosinusitis (CRS) influenced the
asthma response to Omalizumab treatment.
Methods
This study retrospectively analysed data from 70 patients
with severe, uncontrolled asthma treated with Omalizu-
mab. A skin prick test (SPT) was performed in all patients.
In serum, specific Immunoglobulin E (IgE) to Staphylococ-
cal enterotoxins (SE) and total IgE were measured by
Immunocap. Asthma response was evaluated by physi-
cian’s Global Evaluation of Treatment Effectiveness
(GETE-score); GETE 0, 1 and 2 were considered as non-
responders, GETE 3 and 4 as responders.
Results
The mean age of the patients was 54.4 years and 62% of
them were female. 84.3% of the asthmatics responded to
Omalizumab treatment. Within the total patient group,
55.7% had comorbid nasal polyps and 83.8% had antibo-
dies to staphylococcal enterotoxins in their serum. Within
the SE-IgE positive group, 54.4% had an excellent GETE
score, compared to 30.4% with good score and 14.3% with
moderate GETE-score. A higher SE-IgE concentration was
found in patients with CRS with nasal polyps (CRSwNP)
and a strong correlation between SE-IgE and total IgE was
observed. The proportion of responders tended to be
higher in the group diagnosed with CRSwNP compared to
CRS without nasal polyps (CRSsNP), and higher in
CRSsNP compared to no CRS (89.7% vs. 85.7% vs. 81.8%);
the differences were not statistically significant. The pre-
sence of CRS thus did not reduce the overall high
response rate to Omalizumab.
Conclusions
We here showed that a high proportion of severe uncon-
trolled asthma patients are sensitized to staphylococcal
enterotoxins and more than half of these severe asthmatics
have comorbid nasal polyposis. There is a trend towards a
better asthma response in patients with antibodies to SE
and in patients with CRSwNP.
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